Skip to main content

Table 3 The effect of the type of drug resistance or history of TB treatment on the proportion of treatment success of the two groups

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Indicators BDQ group (n = 102)   Non-BDQ group (n = 100)   p value
  Success Others Success Others  
Type of drug resistance (n, %)      
 RR 3 (100.0) 0 (0.0) 2 (40.0) 3 (60.0) 0.20
 MDR 69 (93.2) 5 (6.8) 47 (69.1) 21 (30.9) < 0.001*
 XDR 22 (88.0) 3 (12.0) 14 (51.9) 13 (48.1) 0.005*
History of TB treatment (n, %)      
 New cases 10 (90.9) 1 (9.1) 6 (75.0) 2 (25.0) 0.55
 One-time history of TB treatment 34 (91.9) 3 (8.1) 18 (72.0) 7 (28.0) 0.04*
 Two-time history of TB treatment 29 (90.6) 3 (9.4) 27 (71.1) 11 (28.9) 0.04*
 ≥ Three-time history of TB treatment 21 (95.5) 1 (4.5) 12 (41.4) 17 (58.6) < 0.001*
 MDR/RR-TB (n = 77)   (n = 73)   
 New cases 7 (100.0) 0 (0.0) 5 (71.4) 2 (28.6) 0.46
 One-time history of TB treatment 30 (90.9) 3 (9.1) 16 (76.2) 5 (23.8) 0.14
 Two-time history of TB treatment 21 (95.5) 1 (4.5) 20 (76.9) 6 (23.1) 0.07
 ≥ Three-time history of TB treatment 14 (93.3) 1 (6.7) 8 (42.1) 11 (57.9) 0.003*
 XDR-TB (n = 25)   (n = 27)   
 New cases 3 (75.0) 1 (25.0) 1 (100.0) 0 (0.0) 1.00
 One-time history of TB treatment 4 (100.0) 0 (0.0) 2 (50.0) 2 (50.0) 0.432
 Two-time history of TB treatment 8 (80.0) 2 (20.0) 7 (77.8) 5 (22.2) 1.00
 ≥ Three-time history of TB treatment 7 (100.0) 0 (0.0) 4 (40.0) 6 (60.0) 0.04*
  1. TB tuberculosis, n number, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, BDQ bedaquiline
  2. * the differences had statistical significance (p < 0.05)